
Last updated: 2026-10-14 23:27:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Immunovant, Inc. (IMVT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $27.91, with a market capitalisation of $6.09B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16.77 to $45.42. This page covers its latest market performance, valuation, price trends and company information.
$6.09B | |
$28.46 | |
$53.75 | |
$3.15 | |
$28.71 | |
1.41M | |
1.28M | |
-- | |
$45.42 | |
$16.77 | |
-- | |
-- |
Immunovant, Inc. (IMVT) is trading at $27.94 in after-hours trading as of 2026-10-14 22:09:00, down 2.70% ($0.78) from the regular-session close of $28.71.
After-hours trading shows how investors are pricing IMVT after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Immunovant, Inc. (IMVT) moved from $33.25 to $27.91, representing a decline of 16.06% ($5.34).
The stock traded between $27.84 and $33.99 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.52 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 38.9%
IMVT is currently trading at $27.91, placing it 38.9% of the way from its 52-week low of $16.77 to its 52-week high of $45.42. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 315 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Immunovant, Inc. (IMVT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.